Most Popular
1. THE INFLATION MONSTER is Forecasting RECESSION - Nadeem_Walayat
2.Why APPLE Could CRASH the Stock Market! - Nadeem_Walayat
3.The Stocks Stealth BEAR Market - Nadeem_Walayat
4.Inflation, Commodities and Interest Rates : Paradigm Shifts in Macrotrends - Rambus_Chartology
5.Stock Market in the Eye of the Storm, Visualising AI Tech Stocks Buying Levels - Nadeem_Walayat
6.AI Tech Stocks Earnings BloodBath Buying Opportunity - Nadeem_Walayat
7.PPT HALTS STOCK MARKET CRASH ahead of Fed May Interest Rate Hike Meeting - Nadeem_Walayat
8.50 Small Cap Growth Stocks Analysis to CAPITALISE on the Stock Market Inflation -Nadeem_Walayat
10.Apple and Microsoft Nuts Are About to CRACK and Send Stock Market Sharply Lower - Nadeem_Walayat
Last 7 days
UK Housing Market Analysis, Trend Forecast 2022 to 2025 - Part 2 - 30th June 22
Stock Market Turning the Screws - 30th June 22
How to Ignore Stocks (and why you should) - 30th June 22
Top Tips For Getting The Correct Insurance Option For Your Needs - 30th June 22
Central Banks Plan To Buy More Gold In 2022 - 30th June 22
AI Tech Stock PORTFOLIO NAME OF THE GAME - 29th June 22
Rebounding Crude Oil Gets Far Away from the Bearish Side - 29th June 22
UK House Prices - Lets Get Jiggy With UK INTEREST RATES - 28th June 22
This “Bizarre” Chart is Wrecking the Stock Market - 28th June 22
Recession Question Answered - 28th June 22
Technical Analysis: Why You Should Expect a Popularity Surge - 28th June 22
Have US Bonds Bottomed? - 27th June 22
Gold Junior Miners: A Bearish Push Is Coming to Move Them Lower - 27th June 22
Stock Market Watching Out - 27th June 22
The NEXT BIG EMPIRE WILL BE..... CANZUK - 25th June 22
Who (or What) Is Really in Charge of Bitcoin's Price Swings? - 25th June 22
Crude Oil Price Forecast - Trend Breaks Downward – Rejecting The $120 Level - 25th June 22
Everyone and their Grandma is Expecting a Big Stocks Bear Market Rally - 23rd June 22
The Fed’s Hawkish Bite Left Its Mark on the S&P 500 Stocks - 23rd June 22
No Dodging the Stock Market Bullet - 23rd June 22
How To Set Up A Business To Better Manage In The Free Market - 23rd June 22
Why Are Precious Metals Considered A Good Investment? Find Out Here - 23rd June 22
UK House Prices and the Inflation Mega-trend - 22nd June 22
Sportsbook Betting Reviews: How to Choose a Sportsbook- 22nd June 22
Looking to buy Cannabis Stocks? - 22nd June 22
UK House Prices Momentum Forecast - 21st June 22
The Fed is Incompetent - Beware the Dancing Market Puppet - 21st June 22
US Economy Headed for a Hard Landing - 21st June 22
How to Invest in EU - New Opportunities Uncovered - 21st June 22
How To Protect Your Assets During Inflation - 21st June 22

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Big Upside in this "Life or Death" Stock Market Sector

Stock-Markets / Healthcare Sector Sep 27, 2009 - 03:43 PM GMT

By: GrowthStockWire


The diagnostics industry was once regarded as a red-headed stepchild for medical investors.

Focused on cheap tests for cholesterol and blood sugar, the market quickly became commoditized. Size, scale, and consolidation overran the industry. Anyone with access to low-wage technicians could enter this game.

Things have changed. Diagnostics now does $50 billion in annual business. The technology is increasingly sophisticated. Trained geneticists and molecular biologists run tests with huge price tags. The rewards for early investors can be huge...

Today, I'm most interested in a hidden and ultra-fast-growing subsector of medical testing market: cancer diagnostics. Here, speed and accuracy is critical for life-or-death decisions. And the companies with the best technologies own the market.

Take leukemia diagnostics...

Mutations in more than 50 genes can contribute to or exacerbate the progression of leukemia. Diagnosis is time-consuming and expensive, on average $3,000 per procedure. But identifying the right disease fast is absolutely critical...

Chronic myelogenous leukemia (CML), for example, is a rare blood disorder that springs from a single genetic alteration. Because the disease's early stages come with no symptoms, some CML patients go undiagnosed for months. If caught too late, CML can kill within weeks. But if doctors pick it up early enough, one "miracle drug" – Gleevac – can help CML patients live more than eight years with the disease.

But Gleevec is utterly worthless in other leukemias, including the genetically similar (and equally devastating) acute lymphoblastic leukemia. These patients are limited to chemotherapy, radiation, and bone marrow transplant. An imprecise diagnosis can waste crucial days and weeks.

Today, cancer diagnostics is a $6 billion market. It's growing more than 10% a year. And this growth rate will pick up in the years ahead. Here's why:

Cancer remains one of the leading causes of death worldwide. Roughly 15% of the population gets some form of the disease at some point in their life. In the U.S. alone, more than 1.5 million new cancer diagnoses are made every year.

Hundreds of companies are clamoring for a piece of the growing cancer diagnostics market. Two of my favorites are Genomic Health (GHDX) and Myriad Genetics (MYGN). Each offer testing products for breast cancer.

Myriad sells a screening test for women who come from families with a history of breast cancer. Women pre-disposed to the disease have a chance to pursue preventative medical strategies. Genomic Health's test predicts whether a patient's breast cancer will respond to chemotherapy or not, based on a tumor's molecular "fingerprint."

With the coming growth in the diagnostics industry, both Genomic and Myriad are attractive long-term investments at current prices. These companies have the technology and expertise to dominate their niche. And their products can mean the difference between life and death.

Good investing,

Rob Fannon

The Growth Stock Wire is a free daily e-letter that provides readers with a pre-market briefing on the most profitable opportunities in the global stock, currency, and commodity markets. Written by veteran trader Jeff Clark, and featuring expert guest commentaries, Growth Stock Wire is delivered to your inbox each weekday morning before the markets open.

Customer Service: 1-888-261-2693 – Copyright 2009 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

Growth Stock Wire Archive

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in